Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Hauser

Showing results (11-20 of 266) with videos related to

Pageof 27
Sort By:
Evidence-Based Medicine|December 20, 2014
Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's diseaseRobert A Hauser
Expert Opinion on Pharmacotherapy|March 23, 2007
Duodenal levodopa infusion for the treatment of Parkinson's diseaseJohan Samanta, Robert A Hauser
JAMA Neurology|November 9, 2017
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced DyskinesiaRajesh Pahwa, Robert A Hauser
Movement Disorders : Official Journal of the Movement Disorder Society|March 26, 2011
Determination of minimal clinically important change in early and advanced Parkinson's diseaseRobert A Hauser, Peggy Auinger,
Journal of the Neurological Sciences|February 17, 2018
Tardive dyskinesia: Out of the shadowsRobert A Hauser, Daniel Truong
Expert Review of Neurotherapeutics|July 25, 2024
Current use of neurotoxins for alleviating symptoms of cervical dystoniaStephen Aradi, Robert A Hauser
Therapeutic Advances in Neurological Disorders|December 25, 2010
Improving symptom control in early Parkinson's diseaseStuart H Isaacson, Robert A Hauser
Neurologic Clinics|October 27, 2004
Future therapies for Parkinson's diseaseRobert A Hauser, Kelly E Lyons
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|March 18, 2011
[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromesRobert A Hauser, Donald G Grosset
Drugs & Aging|June 25, 2005
Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experienceRobert A Hauser, Michael A Schwarzschild
Pageof 27

Showing results (11-20 of 266) with videos related to

Sort By:
Pageof 27
Evidence-Based Medicine|December 20, 2014
Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's diseaseRobert A Hauser
Expert Opinion on Pharmacotherapy|March 23, 2007
Duodenal levodopa infusion for the treatment of Parkinson's diseaseJohan Samanta, Robert A Hauser
JAMA Neurology|November 9, 2017
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced DyskinesiaRajesh Pahwa, Robert A Hauser
Movement Disorders : Official Journal of the Movement Disorder Society|March 26, 2011
Determination of minimal clinically important change in early and advanced Parkinson's diseaseRobert A Hauser, Peggy Auinger,
Journal of the Neurological Sciences|February 17, 2018
Tardive dyskinesia: Out of the shadowsRobert A Hauser, Daniel Truong
Expert Review of Neurotherapeutics|July 25, 2024
Current use of neurotoxins for alleviating symptoms of cervical dystoniaStephen Aradi, Robert A Hauser
Therapeutic Advances in Neurological Disorders|December 25, 2010
Improving symptom control in early Parkinson's diseaseStuart H Isaacson, Robert A Hauser
Neurologic Clinics|October 27, 2004
Future therapies for Parkinson's diseaseRobert A Hauser, Kelly E Lyons
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|March 18, 2011
[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromesRobert A Hauser, Donald G Grosset
Drugs & Aging|June 25, 2005
Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experienceRobert A Hauser, Michael A Schwarzschild
Pageof 27